STOCK TITAN

Recursion Pharmaceuticals (RXRX) Financials

RXRX NASDAQ
Trailing 12 months to September 30, 2026
Revenue $68.2M +56.2% YoY
Net Income -$475.7M n/m YoY
EPS (Diluted) -$0.86 YoY not available
Free Cash Flow -$312.5M n/m YoY
Market Cap $1.7B as of Nov 17, 2026
Price / Sales 24.8x on $68.2M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 1.9x on $905.8M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RXRX SEC filings page.

Recursion Pharmaceuticals, Inc. (RXRX) reported $68.2M in revenue over the twelve months to Sep 30, 2026, up 56.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RXRX FY2025

Recursion remains a development-stage business: revenue is growing, but research spending and operating losses are expanding faster than commercial output.

Revenue grew 26.9% while cost of revenue grew 56.8% in FY2025. Gross margin then fell 18.1 percentage points to 5.0%, so added activity did not translate into better unit economics.

R&D consumed 636.4% of revenue in FY2025, while operating cash flow was -$371.8M; this is a research-led model in which commercial receipts currently fund only a small fraction of development spending. Free cash flow was -$378.3M, close to operating cash flow, indicating capital spending was not the main source of cash consumption.

Liabilities fell 17.0% in FY2025 while current liabilities fell 21.2%, reducing balance-sheet pressure. Yet financing cash flow supplied $521.5M while operations recorded -$371.8M, showing that reported liquidity is being supported externally rather than generated by the business. The reported liquidity comparison was 24 months, a balance-to-outflow measure rather than evidence that operations funded themselves.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 57 / 100
Financial Health Score 57/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Recursion Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
52

Recursion Pharmaceuticals, Inc. held $743.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $371.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Recursion Pharmaceuticals, Inc. scores 52/100 among other emerging companies.

Dilution
23

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Recursion Pharmaceuticals, Inc. scores 23/100 on it among other emerging companies.

R&D Intensity
85

Recursion Pharmaceuticals, Inc. spent $475.3M on research and development in fiscal year 2025, which was 65.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Recursion Pharmaceuticals, Inc. scores 85/100 among other emerging companies.

Revenue Progress
70

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Recursion Pharmaceuticals, Inc. scores 70/100 on it among other emerging companies.

Burn Trend
36

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Recursion Pharmaceuticals, Inc. scores 36/100 on it among other emerging companies.

Balance Sheet
76

Recursion Pharmaceuticals, Inc.'s cash, cash equivalents and investments came to $743.3M at the end of fiscal year 2025, against $343.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Recursion Pharmaceuticals, Inc. scores 76/100 among other emerging companies.

Altman Z-Score Distress
0.13

Recursion Pharmaceuticals, Inc. scores 0.13, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $2.1B against total assets of $1.5B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
4/9

Recursion Pharmaceuticals, Inc. passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing
N/A

Recursion Pharmaceuticals, Inc. reported a net loss of $644.8M while operations used $371.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Recursion Pharmaceuticals, Inc. reported an operating loss of $648.1M against $1.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$18.6M
YoY+258.5%
QoQ+141.9%
5Y CAGR+48.9%

Recursion Pharmaceuticals, Inc. generated $18.6M in revenue in Q3 2026. This represents an increase of 258.5% from the same quarter a year earlier. Against the prior quarter it is up 141.9%.

EBITDA
-$106.6M
YoYn/m
QoQn/m
5Y CAGRn/m

Recursion Pharmaceuticals, Inc.'s EBITDA was -$106.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$119.0M
YoYn/m
QoQn/m
5Y CAGRn/m

Recursion Pharmaceuticals, Inc. reported a net loss of $119.0M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.22
YoYn/m
QoQn/m
5Y CAGRn/m

Recursion Pharmaceuticals, Inc. earned -$0.22 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$77.8M
YoYn/m
QoQn/m
5Y CAGRn/m

Recursion Pharmaceuticals, Inc. recorded an outflow of $77.8M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$549.9M
YoY-16.7%
QoQ+0.8%
5Y CAGR+6.9%

Recursion Pharmaceuticals, Inc. held $549.9M in cash against $93K in long-term debt as of Q3 2026.

Shares Outstanding
623M
YoY+19.6%
QoQ+16.3%
5Y CAGR+29.8%

Recursion Pharmaceuticals, Inc. had 623M shares outstanding in Q3 2026. This represents an increase of 19.6% from the same quarter a year earlier. Against the prior quarter it is up 16.3%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
45.9%
QoQ+95.7pp
5Y change-54.1pp

Recursion Pharmaceuticals, Inc.'s gross margin was 45.9% in Q3 2026, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is up 95.7 percentage points. No change is given against Q3 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity
-13.1%
YoY+2.4pp
QoQ+1.2pp
5Y change-5.2pp

Recursion Pharmaceuticals, Inc.'s quarterly ROE was -13.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 2.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$99.1M
YoY-18.1%
QoQ+10.6%
5Y CAGR+24.4%

Recursion Pharmaceuticals, Inc. invested $99.1M in research and development in Q3 2026. This represents a decrease of 18.1% from the same quarter a year earlier. Against the prior quarter it is up 10.6%.

Capital Expenditures
$407K
YoY+67.5%
QoQ+825.0%
5Y CAGR-47.0%

Recursion Pharmaceuticals, Inc. invested $407K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 67.5% from the same quarter a year earlier. Against the prior quarter it is up 825.0%.

Share Buybacks

Not reported for Q3 2026.

RXRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RXRX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$18.6M+258.5%$7.7M-60.1%$6.5M-56.1%$35.5M+681.7%$5.2M-80.2%$19.2M+33.3%$14.7M+6.9%$4.5M-58.3%
Cost of Revenue$10.0M-31.6%$11.5M-43.0%$12.5M-42.8%$14.3M+11.6%$14.7M+21.6%$20.2M+119.2%$21.8M+95.5%$12.8M+29.5%
Gross Profit$8.5Mn/m-$3.8Mn/m-$6.0Mn/m$21.3Mn/m-$9.5M-167.9%-$938K-118.0%-$7.1M-369.6%-$8.2M-915.8%
R&D Expenses$99.1M-18.1%$89.6M-30.3%$87.9M-32.2%$95.9M-2.4%$121.1M+62.3%$128.6M+74.0%$129.6M+91.9%$98.3M+41.5%
SG&A Expenses$32.6M-21.8%$41.5M-11.0%$34.6M-36.7%$33.7M-56.4%$41.6M+10.3%$46.7M+46.6%$54.6M+74.0%$77.2M+153.4%
Operating Income-$123.2Mn/m-$135.0Mn/m-$128.5Mn/m-$108.3Mn/m-$172.2Mn/m-$176.2Mn/m-$191.4Mn/m-$183.8Mn/m
EBITDA-$106.6Mn/m-$116.8Mn/m-$108.8Mn/m-$88.9Mn/m-$151.2Mn/m-$152.4Mn/m-$172.0Mn/m-$170.8Mn/m
Interest Expense$266K-68.1%$309K-35.6%$350K-31.1%-$11K-101.8%$833K+50.6%$480K+21.8%$508K+2440.0%$605K+2140.7%
Income Tax$25K+733.3%-$1Kn/m-$4.6Mn/m$19K+137.5%$3K-98.2%$0n/m-$158Kn/m$8Kn/m
Net Income-$119.0Mn/m-$131.0Mn/m-$117.5Mn/m-$108.1Mn/m-$162.3Mn/m-$171.9Mn/m-$202.5Mn/m-$178.9Mn/m
EPS (Basic)-$0.22n/m-$0.25n/m-$0.22n/m-$0.17-$0.36-$0.41-$0.50-$0.57n/m
EPS (Diluted)-$0.22n/m-$0.25n/m-$0.22n/m-$0.17-$0.36-$0.41-$0.50-$0.57n/m
Diluted Shares (Avg)543M+21.5%532M+27.6%529M+31.4%N/A447M417M403MN/A

RXRX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RXRX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$1.2B-12.7%$1.2B-6.9%$1.3B+2.6%$1.5B+1.8%$1.4B+92.6%$1.3B+67.9%$1.3B+134.0%$1.4B+121.6%
Current Assets$616.0M-13.7%$603.5M+2.8%$709.6M+21.5%$812.8M+13.8%$714.1M+50.6%$587.2M+12.4%$584.1M+70.0%$714.3M+63.0%
Cash & Equivalents$549.9M-16.7%$545.7M+3.9%$654.5M+30.8%$743.3M+25.1%$659.8M+54.3%$525.1M+10.7%$500.5M+68.9%$594.4M+51.8%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$160.7M-0.8%$160.3M-2.4%$160.2M+1.3%$162.2M+8.9%$162.0M+211.3%$164.3M+215.6%$158.1M+203.7%$148.9M+186.0%
Total Liabilities$315.9M-10.4%$297.7M-22.3%$314.8M-15.2%$343.3M-17.0%$352.6M+74.6%$383.2M+100.2%$371.3M+136.9%$413.8M+117.5%
Current Liabilities$122.9M-20.8%$119.9M-26.9%$129.7M-8.7%$147.7M-21.2%$155.1M+42.4%$164.0M+90.5%$142.0M+92.1%$187.5M+101.2%
Non-Current Liabilities$193.0M-2.3%$177.8M-18.9%$185.1M-19.3%$195.6M-13.6%$197.5M+112.2%$219.2M+108.1%$229.3M+177.0%$226.3M+133.1%
Long-Term Debt$93K-99.2%$4.8M-66.5%$7.2M-56.3%$9.6M-49.7%$11.9M-42.0%$14.2M-38.1%$16.4M+1435.6%$19.0M+1627.7%
Total Equity$905.8M-13.5%$915.0M-0.5%$1.0B+9.7%$1.1B+9.3%$1.0B+99.6%$919.1M+57.3%$933.9M+132.8%$1.0B+123.3%
Retained Earnings-$2.4Bn/m-$2.3Bn/m-$2.2Bn/m-$2.1Bn/m-$2.0Bn/m-$1.8Bn/m-$1.6Bn/m-$1.4Bn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable.

RXRX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RXRX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$77.4Mn/m-$105.9Mn/m-$81.1Mn/m-$46.1Mn/m-$117.4Mn/m-$76.4Mn/m-$132.0Mn/m-$115.4Mn/m
Depreciation & Amortization$16.5M-21.4%$18.2M-23.8%$19.7M+1.8%$19.5M+50.4%$21.0M+192.3%$23.8M+165.9%$19.3M+162.0%$13.0M+71.5%
Stock-Based CompensationN/A$19.3M-25.2%$22.2M-38.4%N/A$25.0M+41.1%$25.8M+61.7%$36.1M+123.6%N/A
Capital Expenditures$407K+67.5%$44K-98.6%$258K-85.9%$1.2M-4.2%$243K-94.7%$3.1M+166.5%$1.8M-72.5%$1.3M-37.2%
Free Cash Flow-$77.8Mn/m-$106.0Mn/m-$81.4Mn/m-$47.3Mn/m-$117.6Mn/m-$79.6Mn/m-$133.8Mn/m-$116.7Mn/m
Investing Cash Flow-$407Kn/m-$2.0Mn/m-$338Kn/m-$1.2M-100.5%-$2.5Mn/m-$5.8Mn/m-$7.3Mn/m$275.5Mn/m
Financing Cash Flow$83.1M-66.9%-$1.3M-101.3%-$3.5M-108.6%$132.0M+1140.8%$251.3M+1426.8%$97.7M-62.9%$40.5M+191.6%$10.6M-86.8%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

RXRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RXRX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin45.9%-49.8%-44.9pp-93.0%-44.9pp59.8%-183.8%-4.9%-41.1pp-48.0%-67.1pp-181.4%
Operating Margin-664.0%-1759.7%-1985.6%-304.8%-3327.6%-916.8%-1297.9%-4042.4%
Net Margin-641.6%-1708.0%-1815.6%-304.2%-3135.3%-894.2%-1373.3%-3935.5%
Return on Equity-13.1%+2.4pp-14.3%+4.4pp-11.5%+10.2pp-9.6%+7.7pp-15.5%+2.8pp-18.7%-2.0pp-21.7%+1.1pp-17.3%+2.8pp
Return on Assets-9.7%+1.9pp-10.8%+2.4pp-8.8%+6.7pp-7.3%+5.0pp-11.6%+1.6pp-13.2%-0.6pp-15.5%+0.9pp-12.3%+1.9pp
Current Ratio5.01+0.4x5.03+1.5x5.47+1.4x5.50+1.7x4.60+0.2x3.58-2.5x4.11-0.5x3.81-0.9x
Debt-to-Equity0.000.0x0.010.0x0.010.0x0.010.0x0.010.0x0.020.0x0.020.0x0.020.0x
Liabilities-to-Equity0.350.0x0.33-0.1x0.31-0.1x0.30-0.1x0.340.0x0.42+0.1x0.400.0x0.400.0x
Asset Turnover0.020.0x0.010.0x0.000.0x0.020.0x0.000.0x0.010.0x0.010.0x0.000.0x
FCF Margin-419.4%-1381.9%-1257.1%-133.1%-2272.5%-413.9%-907.4%-2567.7%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Recursion Pharmaceuticals, Inc. RXRX FY2025 $74.7M -$644.8M N/A $1.7B 57/100
Fortrea Holdings Inc. FTRE FY2025 $2.7B -$986.2M -36.2% $1.9B 22/100
Maze Therapeutics, Inc. MAZE FY2025 N/A -$131.1M N/A $1.8B —
Zymeworks Inc. ZYME FY2025 $106.0M -$81.1M -76.6% $1.8B 79/100
Nurix Therapeutics, Inc. NRIX FY2025 $84.0M -$264.5M N/A $1.6B 55/100
Zenas BioPharma, Inc. ZBIO FY2025 $10.0M -$377.7M N/A $1.9B 37/100

Frequently Asked Questions

Recursion Pharmaceuticals, Inc. (RXRX) reported $74.7M in total revenue for fiscal year 2025. This represents a 26.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Recursion Pharmaceuticals, Inc. (RXRX) revenue grew by 26.9% year-over-year, from $58.8M to $74.7M in fiscal year 2025.

No, Recursion Pharmaceuticals, Inc. (RXRX) reported a net loss of $475.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $644.8M.

Recursion Pharmaceuticals, Inc. (RXRX) reported diluted earnings per share of -$1.44 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Recursion Pharmaceuticals, Inc. (RXRX) had EBITDA of -$564.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Recursion Pharmaceuticals, Inc. (RXRX) had $743.3M in cash and equivalents against $9.6M in long-term debt.

Recursion Pharmaceuticals, Inc. (RXRX) had a gross margin of 5.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Recursion Pharmaceuticals, Inc. (RXRX) has a return on equity of -57.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Recursion Pharmaceuticals, Inc. (RXRX) recorded an outflow of $378.3M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Recursion Pharmaceuticals, Inc. (RXRX) recorded an outflow of $371.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Recursion Pharmaceuticals, Inc. (RXRX) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.

Recursion Pharmaceuticals, Inc. (RXRX) invested $6.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Recursion Pharmaceuticals, Inc. (RXRX) invested $475.3M in research and development during fiscal year 2025.

Recursion Pharmaceuticals, Inc. (RXRX) had 527M shares outstanding as of fiscal year 2025.

Recursion Pharmaceuticals, Inc. (RXRX) had a current ratio of 5.50 as of fiscal year 2025, which is generally considered healthy.

Recursion Pharmaceuticals, Inc. (RXRX) had a debt-to-equity ratio of 0.01 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Recursion Pharmaceuticals, Inc. (RXRX) had a liabilities-to-equity ratio of 0.30 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Recursion Pharmaceuticals, Inc. (RXRX) had a return on assets of -43.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Recursion Pharmaceuticals, Inc. (RXRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.7B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Recursion Pharmaceuticals, Inc. (RXRX) trades at 24.8x sales, its market capitalization divided by $68.2M revenue, trailing 12 months to September 30, 2026. The market capitalization is $1.7B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Recursion Pharmaceuticals, Inc. (RXRX) held $743.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $371.8M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Recursion Pharmaceuticals, Inc. (RXRX) has an Altman Z-Score of 0.13, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Recursion Pharmaceuticals, Inc. (RXRX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Recursion Pharmaceuticals, Inc. (RXRX) reported a net loss of $644.8M while operations used $371.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Recursion Pharmaceuticals, Inc. (RXRX) reported an operating loss of $648.1M against $1.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Recursion Pharmaceuticals, Inc. (RXRX) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top